TSS
CRSP icon

Two Sigma Securities’s CRISPR Therapeutics CRSP Stock Holding History

Two Sigma Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,300
Closed -$343K – 1957
2024
Q3 		$343K Sell
7,300
-27,400
-79% -$1.39M 0.01% 1625
2024
Q2 		$1.87M Buy
34,700
+6,600
+23% +$382K 0.02% 742
2024
Q1 		$1.92M Sell
28,100
-23,500
-46% -$1.68M 0.02% 773
2023
Q4 		$3.23M Buy
51,600
+27,000
+110% +$1.49M 0.03% 506
2023
Q3 		$1.12M Buy
24,600
+3,300
+15% +$170K 0.01% 968
2023
Q2 		$1.2M Buy
+21,300
New +$1.21M 0.02% 863
2023
Q1 		– Sell
-14,600
Closed -$593K – 2761
2022
Q4 		$593K Sell
14,600
-9,100
-38% -$483K 0.02% 969
2022
Q3 		$1.55M Buy
23,700
+18,900
+394% +$1.37M 0.05% 450
2022
Q2 		$292K Sell
4,800
-3,000
-38% -$176K 0.01% 1321
2022
Q1 		$490K Buy
+7,800
New +$490K 0.02% 1031
2021
Q3 		– Sell
-3,300
Closed -$534K – 1615
2021
Q2 		$534K Buy
+3,300
New +$401K 0.02% 629

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Securities's CRSP Position: Q2 2026 in Review

Two Sigma Securities opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 10,341 shares worth $564K. The stake represents 0.05% of the portfolio and ranks #529 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in CRSP as recently as Q2 2023.

Two Sigma Securities first reported a position in CRSP in Q2 2021 and has held it in 7 quarters since. The position peaked at $687K in Q3 2022. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Two Sigma Securities held 10,341 shares of CRISPR Therapeutics worth $564K as of Q2 2026.
  • CRISPR Therapeutics was a new Two Sigma Securities position in Q2 2026.
  • CRISPR Therapeutics made up 0.05% of Two Sigma Securities's portfolio in Q2 2026, its #529 holding.
  • Two Sigma Securities first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • Two Sigma Securities's CRISPR Therapeutics position peaked at $687K in Q3 2022.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.